CSBR CHAMPIONS ONCOLOGY, INC.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 771856 · Fiscal year ends 04/30
Financial factors as of 2026-07-31 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY6.7%
TTM net income YoY-137.8%
TTM EPS YoY—
Revenue 3-yr CAGR4.8%
Net income 3-yr CAGR—
Margins
Gross margin49.8%
Operating margin-1.7%
Net margin-1.8%
FCF margin-10.1%
EBITDA margin0.5%
Returns
ROE-29.8%
ROA-3.5%
ROIC (approx.)—
Asset turnover1.90x
Leverage & solvency
Liabilities / assets86.6%
Debt / equity0.00x
Current ratio1.03x
Interest coverage—
Cash quality & payout
Operating cash flow / net income5.04x
Accruals ratio14.0%
Payout ratio—
Capex / revenue0.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q12026-07-31 | 2026Q4*2026-04-30 | 2026Q32026-01-31 | 2026Q22025-10-31 | 2026Q12025-07-31 | 2025Q4*2025-04-30 | 2025Q32025-01-31 | 2025Q22024-10-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $15.23M | $13.84M | $16.56M | $15.04M | $13.99M | $12.36M | $17.04M | $13.49M |
| Cost of revenue | $7.53M | $6.81M | $8.83M | $7.26M | $8.00M | $7.27M | $6.62M | $7.43M |
| Gross profit | $7.70M | $7.03M | $7.72M | $7.77M | $6.00M | $5.08M | $10.42M | $6.06M |
| R&D expense | $2.34M | $2.12M | $2.27M | $2.62M | $2.08M | $1.96M | $1.72M | $1.69M |
| SG&A expense | $2.67M | $2.63M | $2.98M | $2.97M | $2.57M | $2.53M | $2.40M | $1.89M |
| Operating income | -$409,000 | -$522,000 | -$276,000 | $185,000 | -$527,000 | -$2.01M | $4.50M | $732,000 |
| Pretax income | -$415,000 | -$495,000 | -$237,000 | $255,000 | -$452,000 | -$1.96M | $4.52M | $739,000 |
| Income tax | $11,000 | $172,000 | $42,000 | $18,000 | $14,000 | -$129,000 | $23,000 | $11,000 |
| Net income | -$426,000 | -$667,000 | -$279,000 | $268,000 | -$466,000 | -$1.83M | $4.50M | $728,000 |
| EBITDA | -$95,000 | -$222,000 | $65,000 | $542,000 | -$169,000 | -$1.61M | $4.90M | $1.13M |
| EPS (basic) | -0.03 | — | -0.02 | 0.02 | -0.03 | — | 0.33 | 0.05 |
| EPS (diluted) | — | — | -0.02 | 0.02 | -0.03 | — | 0.31 | 0.05 |
| Weighted avg. shares (diluted) | — | — | 13.89M | 14.46M | 13.79M | — | 14.36M | 14.02M |
| Balance sheet | ||||||||
| Cash & equivalents | $4.36M | $4.87M | $7.13M | $8.52M | $10.32M | $9.79M | $3.20M | $2.75M |
| Receivables | $13.60M | $13.18M | $12.07M | $11.54M | $9.47M | $11.20M | $15.78M | $10.47M |
| Current assets | $19.29M | $19.22M | $20.18M | $21.33M | $21.01M | $22.36M | $19.70M | $14.08M |
| PP&E, net | $3.79M | $3.53M | $3.71M | $3.95M | $4.23M | $4.38M | $5.04M | $4.97M |
| Goodwill | $335,000 | $335,000 | $335,000 | $335,000 | $335,000 | $335,000 | $335,000 | $335,000 |
| Total assets | $33.29M | $26.99M | $28.45M | $30.16M | $30.55M | $32.34M | $30.63M | $25.24M |
| Current liabilities | $18.73M | $19.92M | $20.68M | $22.14M | $22.70M | $23.85M | $19.87M | $18.86M |
| Total liabilities | $28.83M | $22.92M | $24.07M | $25.93M | $27.01M | $28.57M | $25.16M | $24.56M |
| Shareholders' equity | $3.89M | $3.94M | $4.28M | $4.17M | $3.51M | $3.77M | $5.47M | $681,000 |
| Shares outstanding | 13.92M | 13.89M | 13.89M | 13.89M | 13.79M | 13.78M | 13.71M | 13.70M |
| Cash flow statement | ||||||||
| Operating cash flow | -$492,000 | -$2.00M | -$1.34M | -$1.74M | $600,000 | $6.87M | $490,000 | -$283,000 |
| Capital expenditure | $55,000 | $239,000 | $37,000 | $242,000 | $46,000 | $253,000 | $42,000 | $94,000 |
| Free cash flow | -$547,000 | -$2.24M | -$1.38M | -$1.98M | $554,000 | $6.62M | $448,000 | -$377,000 |
| Investing cash flow | -$55,000 | -$238,000 | -$14,000 | -$242,000 | -$46,000 | -$253,000 | -$42,000 | -$94,000 |
| Financing cash flow | $33,000 | -$19,000 | -$36,000 | $168,000 | -$14,000 | -$32,000 | $0 | $239,000 |
| Depreciation & amortization | $314,000 | $300,000 | $341,000 | $357,000 | $358,000 | $400,000 | $398,000 | $399,000 |
| Stock-based compensation | $766,000 | $357,000 | $423,000 | $249,000 | $208,000 | $131,000 | $256,000 | $9,000 |
| Share buybacks | — | — | — | — | — | $0 | $0 | $0 |
Free plan shows the latest 8 periods; Pro shows all 65 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.